Clinical Specialties
Treatment of sarcoma and melanoma
Breast and gastrointestinal malignancies

Board Certification
American Board of Surgery

Research
My research involves the treatment of breast cancer and skin malignancies, especially melanoma, as well as clinical breast cancer research. Other research is conducted in the laboratory studying Thymocyte receptor expression in melanoma. The laboratory has developed a transgenic mouse model for melanoma development, which we hope to use to study the progression and prevention of melanoma.
I am also co-principal investigator on a program project grant from the National Cancer Institute belonging to David Alberts, M.D. This grant is for the study of chemoprevention of skin cancer. The clinical part of the project is to research the effectiveness of vitamins A and E. Volunteers with moderate to severe skin damage are recruited, and the effects of oral vitamin A in one study and topical vitamin E in another are studied.
Finally, I am co-investigator on Several Arizona Cancer Center clinical gene therapy studies funded by Vical, Inc., and coordinated by Evan Hersh, M.D. These involve direct gene transfer with a lipid complex of either a HLA B-7 gene or an interleukin-2 gene. The projects involve patients with incurable malignancies. Their tumors are injected with the HLA B-7 gene or an interleukin-2 gene for the purpose of stimulating the patient's own immune system to fight the malignancy, thus ridding the patient of the tumor.

Selected Publications

• Warneke JA, Grossklaus D, Davis J, Stea B, Bebb G, Taylor C, Hastings R, Villar H. (1995). Influence of local treatment on recurrence rate of ductal carcinoma in-situ. Journal of the American College of Surgeons 180(6): 683.
• Warneke JA, Berger R, Villar H, Stea D. (1996). Lumpectomy and radiation treatment for invasive lobular carcinoma of the breast. The American Journal of Surgery 172(5): 496.
• Stopeck AT, Hersh EM, Akporiaye ET, Grogan T, Harris DT, Schluter S, Unger E, Warneke JA, Stahl S. (1997). Phase I study of immunotherapy of malignant melanoma by direct gene transfer of an allogenic histocompatibility antigen, HLA-B7. Journal of Clinical Oncology, January.
• Alberts DS, Dorr RT, Aickin M, Einspahr J, Quinn J, Nelson MA, Xu MJ, Peng YM, Wymer JA, Goldman R, Bozzo P, Warneke James A, Bowden GT, Gensler H Randomized Double-Blinded, Placebo-Controlled Study of Topical 2-(Difluoromethyl)-dl-ornithine in the Chemoprevention of Actinic Keratosis. Cancer Epidemiology, Biomarkers & Prevention.
• Alberts DS, Dorr RT, Einspahr JG, Aickin M, Saboda K, Xu MJ, Peng YM, Goldman R, Foote J, Warneke J, Salasche S, Roe D, Bowden GT. Chemoprevention of human actinic keratoses by topical 2-(Difluoromethyl)-dl-ornithine. Cancer Epidemiology, Biomarkers and Prevention 9: 1281-1286, 2000.